Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany · Delayed Price · Currency is EUR | Market Cap | 91.54B |
| Revenue (ttm) | 9.99B |
| Net Income (ttm) | 3.13B |
| Shares Out | n/a |
| EPS (ttm) | 12.12 |
| PE Ratio | 29.23 |
| Forward PE | 20.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46 |
| Average Volume | 119 |
| Open | 361.75 |
| Previous Close | 361.00 |
| Day's Range | 352.35 - 361.75 |
| 52-Week Range | 312.65 - 489.20 |
| Beta | 0.46 |
| RSI | 53.72 |
| Earnings Date | Nov 3, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Agree To Buy Vertex Pharmaceuticals At $290, Earn 6.5% Using Options
Investors considering a purchase of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) shares, but cautious about paying the going market price of $416.38/share, might benefit from considering selling puts a...
Artisan Global Opportunities Fund Q3 2025 Portfolio Update
During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. We also added to 3i Group, West Pharmaceutical and Amazon during the quarter. We ended our investment campa...
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities across its pipeline. Read the latest analysis on the stock here.
Committee stocks on the move: Uber and Vertex Pharma
The Investment Committee discuss some of their stocks on the move today.
Committee stocks on the move: Uber and Vertex Pharma
The Investment Committee discuss some of their stocks on the move today.
RBC Capital Maintains Vertex Pharmaceuticals (VRTX) Rating, Lowers Price Target | VRTX Stock News
RBC Capital Maintains Vertex Pharmaceuticals (VRTX) Rating, Lowers Price Target | VRTX Stock News
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
VRTX: Stifel Lowers Price Target While Maintaining Hold Rating | VRTX Stock News
VRTX: Stifel Lowers Price Target While Maintaining Hold Rating | VRTX Stock News
Columbia Balanced Fund Q3 2025 Portfolio Update
Electronic Arts' shares outperformed the broader market during the period, driven by renewed investor confidence and momentum surrounding several high-profile product announcements. eBay's shares surg...
Vertex Pharmaceuticals Incorporated 2025 Q3 - Results - Earnings Call Presentation
2025-11-03. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q3 earnings call.
Vertex Pharmaceuticals (VRTX) Reports Strong Q3 2025 Earnings with 11% Revenue Growth
Vertex Pharmaceuticals (VRTX) Reports Strong Q3 2025 Earnings with 11% Revenue Growth
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call Transcript
Q3 2025 Vertex Pharmaceuticals Inc Earnings Call Transcript
Q3 2025 Vertex Pharmaceuticals Inc Earnings Call Transcript
Vertex Pharmaceuticals (VRTX) Beats Q3 Expectations, Shares Fall
Vertex Pharmaceuticals (VRTX) Beats Q3 Expectations, Shares Fall
Vertex Pharmaceuticals (VRTX) Q3 Earnings Surpass Expectations
Vertex Pharmaceuticals (VRTX) Q3 Earnings Surpass Expectations
Vertex Pharmaceuticals Inc. Q3 Profit Increases, Beats Estimates
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced a profit for its third quarter that Increased from the same period last year and beat the Street estimates.
Vertex beats quarterly estimates on cystic fibrosis demand, new drugs
Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer me...
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book
Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.
Vertex Pharmaceuticals Non-GAAP EPS of $4.80 beats by $0.22, revenue of $3.08B beats by $20M
Vertex Reports Third Quarter 2025 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 fin...
Noteworthy Monday Option Activity: VRTX, AXP, BURL
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vertex Pharmaceuticals, Inc. (Symbol: VRTX), where a total of 5,676 contracts have traded s...
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) will release earnings results for the first quarter, after the closing bell on Monday, Nov. 3. Analysts expect the Boston, Massachusetts-based compa...
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results for the first quarter, after the closing bell on Monday, Nov. 3.
After-Hours Earnings Report for November 3, 2025 : PLTR, VRTX, WMB, SPG, O, FANG, FNV, SBAC, BWXT, CTRA, CRBG, HOLX
The following companies are expected to report earnings after hours on 11/03/2025. Visit our Earnings Calendar for a full list of expected earnings releases.Palantir Technologies Inc. (PLTR)is reporti...